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cans [54%] (p < 0.05). Similarly, in patients with asthma, we
found that African American patients were 65% less likely to
have the recommended medication possession rate of at least
80% [RR: 0.35, 95% CI: 0.15–0.81]. There were no signiﬁcant
patient differentials in controller medication adherence by race
in patients with psoriasis.
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OBJECTIVES: To assess the impact of polypharmacy inter-
vention on drug cost in the Medicare Part D population.
METHODS: This is a case-control study, based on 2006
Medicare Part D population. The case group contains cases
which have received Polypharmacy interventions, whereas the
control group contains cases which have not been intervened
upon. Per member per month (PMPM) drug savings were cal-
culated as the difference between the projected post-intervention
drug cost of the case group and the actual post-intervention drug
cost of the case group. The projected post-intervention drug cost
is based on the pre-post intervention percent change in the
PMPM drug cost of the control group. RESULTS: There were
6050 Polypharmacy cases, of which 3442 were intervened on.
The remainder served as the control group. The actual post-inter-
vention PMPM drug cost for the case group was $611 and the
projected post-intervention PMPM drug cost for the same group
was $663, a difference of $52, representing $52 PMPM drug
cost savings. CONCLUSION: Polypharmacy MTMP may not
only help improve therapeutic outcomes through improved med-
ication use, but may also reduce overall health cost. The present
study showed signiﬁcant pharmacy savings as a result of
Polypharmacy intervention. This study did not address medical
cost savings due to the lack of longitudinal medical claim data.
However it would not be unreasonable to assume Polypharmacy
intervention could signiﬁcantly reduce medical cost.
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OBJECTIVES: State Medicaid programs vary drastically in terms
of their prescription drug expenditure per recipient. Prior research
has attempted to explain these variations by identifying potential
determinants of drug expenditure. However, analyses in the past
have been restricted to a few variables and several other poten-
tial determinants and their interactions have not been investi-
gated. Objectives of this study were: a) To identify potential
determinants of Medicaid per capita drug expenditures based on
an established comprehensive model for health services utiliza-
tion; and b) to test impacts of the identiﬁed determinants on per
capita drug expenditures. METHODS: This study employs
Andersen’s Behavior Model of Health Services Utilization to iden-
tify potential determinants of pharmaceutical expenditures in
state Medicaid programs using publicly available data. A struc-
ture equation model was built to test relationships among the
latent constructs of policy, access, predisposing characteristics,
enabling resources, and need for health care, and their inﬂuence
on drug utilization. RESULTS: “Predisposing characteristics”
were found to impact “enabling resources” which, in turn, was
found to signiﬁcantly impact drug utilization. Among the
observed variables, “access to hospitals” and “access to primary
care physicians” signiﬁcantly described “health care resources”;
“risk of diseases” described “need for health care”; and “poverty”
described the latent construct of “enabling resources”. The
“policy” construct was not described adequately by the indica-
tor variables. CONCLUSION: Based on the study results, we con-
clude that Medicaid policy and program interventions, as
described in this model, do not inﬂuence drug costs signiﬁcantly.
Population characteristics like predispositions and enabling
resources determine drug costs in the state Medicaid programs.
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OBJECTIVES: To examine the impact of consumer driven health
plans (CDHPs) on pharmacy and medical utilization, health care
and pharmacy expenditures. METHODS: We utilized enroll-
ment, medical and pharmacy claims data from a national
employer who switched from offering a traditional PPO based
plan (i.e., the “pre” period in 2004) to only offering CDHP
options to their employees in 2005 (i.e., the “post” period).
Patients with select chronic diseases including diabetes and
asthma were included for analyses. Outcomes measured included
total number of prescriptions, disease based medication adher-
ence (estimated by the Medication Possession Ratio (MPR) with
80% or higher classiﬁed as being “adherent”), ER, inpatient and
outpatient visits and pharmacy and health care expenditures.
GEE (Generalized Estimating Equations) for repeated measures
were used because there are 2 correlated observations on each
subject in the dataset adjusting for age, gender, co-morbid risk
scores, family size, coverage status and migration patterns
between the CDHP options. Outcomes variables that were char-
acterized by a large proportion of 0s and extreme right skew
were analyzed using two-part models with logarithmic transfor-
mation of the non-zero observations and a smearing re-trans-
formation. RESULTS: Preliminary results show that for CDHP
switchers there was a reduction in most measures: outpatient
visits reduced by 22%, total number of prescriptions decreased
by 25%, medical and pharmacy expenditures reduced by 22%
and 24% respectively. Individuals were 37% less likely to be
adherent with their drug therapy across all disease states in a
CDHP compared to their adherence in a PPO plan. There were
no appreciable differences in ER and inpatient visits. CON-
CLUSION: Switching to a CDHP resulted in lower utilization of
some services and expenditures. Switching was also associated
with decrease inﬂuenced by CDHP beneﬁt design. CDHPs can
be a useful plan offering but plans should design interventions
to improve medication adherence.
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OBJECTIVES: To assess prescribers’ ability to recognize clini-
cally signiﬁcant DDIs, to examine how DDIs are identiﬁed, and
to evaluate this information source from the prescribers’ per-
spective. METHODS: A postal questionnaire was developed to
assess prescribers’ knowledge of interacting medications. Pre-
scribers were asked to classify 14 drug pairs as “contraindi-
cated”, “may be used together but with monitoring”, or “no
interaction”. An option of “not sure” was provided. The ques-
tionnaires were sent to a national sample of prescribers based on
their past history of DDI prescribing which was determined using
data from a PBM covering over 50 million lives. RESULTS:
Completed questionnaires were obtained from 950 prescribers,
giving an overall response rate of 7.9%. The number of drug
pairs correctly classiﬁed by the prescribers ranged from zero to
thirteen, with a mean of 6 pairs correctly classiﬁed (42.7%). The
percentages of prescribers who correctly classiﬁed speciﬁc drug
pairs ranged from 18.2% for warfarin-cimetidine to 81.2% for
acetaminophen with codeine-amoxicillin. Half of the drug pair
questions were answered “not sure” by over one-third of the
respondents; among which, two were contraindicated. One-
fourth of the prescribers reported using PDAs to learn more
about a DDI, and another one-fourth used printed materials. A
total of 68.4% of the prescribers reported that they were usually
informed by pharmacists about their patients’ potential exposure
to DDIs. Compared to the prescribers who used other sources,
those who used computerized DDI alerts as their usual DDI
information source consistently gave a lower rating score to the
ﬁve statements that assessed the usefulness of the information.
CONCLUSION: This study suggests that prescribers’ DDI
knowledge is insufﬁcient. Physicians mostly commonly learn
about interactions involving their patients from the pharmacy,
suggesting further work is needed to improve the drug prescrib-
ing process to identify potential safety issues earlier in the med-
ication use process.
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OBJECTIVES: To compare adherence and wastage among 30-
day retail program, mandatory 90-day retail program and vol-
untary 90-day retail program. METHODS: This analysis was
conducted using pharmacy claims data from a pharmacy beneﬁt
manager (PBM). Patients who were new to either Ace-Inhibitor,
statins or SSRIs in March-May 2005 were identiﬁed and fol-
lowed-up for a period of 12-month to measure adherence and
wastage. Patients had retail 30-day supply only during the study
period were included in 30-day retail program, patients had
mandatory 90-day supply during the study period were in
mandatory 90-day retail program, and similarly, patients had
voluntary 90-day supply were in voluntary 90-day retail
program. Adherence was assessed in terms of Medication Pos-
session Ratio (MPR). Medication wastage occurred either when
patients switched to different medication within the same class
or to similar medication having different strength and that the
patient’s actual day’s supply was less than dispensed day’s supply.
Medication wastage was measured by the total day’s supply
wasted among a normalized 30-day period. RESULTS: About
955 patients in 30-day retail program, 148 patients in manda-
tory 90-day retail program, and 582 patients in voluntary 90-
day retail program. Adherence was found to be signiﬁcantly
greater in mandatory 90-day (MPR = 0.7543) and voluntary 90-
day retail program (MPR = 0.6895) when compared to 30-day
retail program (MPR = 0.3999) (P < 0.01). Although medication
wastage was found to be relatively higher in mandatory 90-day
retail program (2.5 days/30-day-period), followed by retail 30
program (2.3 days/30-day-period) and voluntary 90-day retail
program (2.2 days/30-day-period), these comparisons were not
signiﬁcant (P > 0.05). CONCLUSION: Adherence was reported
to be signiﬁcantly better for mandatory 90-day retail program
and voluntary 90-day retail program than 30-day retail program;
while medication wastage showed comparable results across the
three programs. This study showed that 90-day supply polices
tend to improve the medication compliance without increasing
the medication wastage.
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OBJECTIVES: Recently, coinsurance has become a common
cost-sharing feature of beneﬁt plans. The objectives were to study
annual trends in out-of-pocket expenditures (OOP) and compare
OOP for patients with chronic conditions with and without
beneﬁt plans requiring coinsurance. METHODS: Inpatient, out-
patient, and prescription utilization and expenditure data from
2002 through 2004 were obtained from the Medstat commer-
cial claims database. Beneﬁt design information was available for
5.9 million adults with claims. Adult patients eligible for both
medical and drug coverage with at least one inpatient or two
outpatient diagnoses of chronic kidney disease (CKD), multiple
sclerosis (MS), rheumatoid arthritis (RA), or diabetes were
selected. Total OOP were calculated by summing copayments,
coinsurance and deductibles for all pharmacy and medical
claims. Annualized OOP for patients whose beneﬁt plans
required medical and/or pharmacy coinsurance inside the
network were compared with patients whose plans did not have
any coinsurance requirements. RESULTS: Total of 32,513
patients with no-coinsurance and 293,907 with co-insurance met
all other selection criteria. Average OOP for patients in co-insur-
ance plans were two to three times greater than those for patients
not in co-insurance plans. During the period from 2002–2004,
average OOP for the sum of outpatient services, drugs and inpa-
tient visits was higher for patients in plans with in-network coin-
surance compared with patients in plans with no coinsurance:
CKD ($2022 vs. $759, P < 0.0001), MS ($1856 vs. $692, P <
0.0001), RA ($1586 vs. $616, P < 0.0001), diabetes ($1384 vs.
$532, P < 0.0001). CONCLUSION: Out-of-pocket expenses are
much higher for patients with insurance plans requiring payment
of coinsurance. The trend toward coinsurance requirements may
limit health care affordability for many patients with serious and
chronic conditions.
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OBJECTIVES: In the past few years a range of policy initiatives
has been introduced into the Australian national reimbursement
system. Prior to these initiatives the Australian Government pub-
lished its “Intergenerational report” which was used to support
the argument that the growth in health, and in particular phar-
maceutical, spending would create a ﬁscal crisis over the next
40-years. In late 2006, after extensive negotiation with industry,
a raft of policies where announced which detailed substantial
